Stocks and Investing
Stocks and Investing
Thu, March 7, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, March 6, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, March 5, 2019
[ 12:00 AM ] - United States, WOPRAI
David Lebovitz Upgraded (ALNY) to Buy on, Mar 5th, 2019
David Lebovitz of Morgan Stanley, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Buy on, Mar 5th, 2019.
David has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, all agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Esther Rajavelu of "UBS" Initiated at Hold on, Wednesday, January 23rd, 2019
- Paul Matteis of "Leerink Swann" Initiated at Hold and Held Target at $63 on, Wednesday, November 28th, 2018
Contributing Sources